

CLAIMS

1. A compound of Formula (I) or (II):


(I);


(II);

or a pharmaceutically acceptable salt thereof, wherein:

B is H or a nucleobase moiety;

W is H, C_1-C_6 alkyl optionally substituted with one or more halogen, or an amino substitution group;

Y is H, C_1-C_6 alkyl optionally substituted with one or more halogen, $-P(R^Y)_2$, $-P(OR^Y)(N(R^Y)_2)$, $-P(=O)(OR^Y)R^Y$, $-P(=S)(OR^Y)R^Y$, $-P(=O)(SR^Y)R^Y$, $-P(=S)(SR^Y)R^Y$, $-P(=O)(OR^Y)_2$, $-P(=S)(OR^Y)_2$, $-P(=O)(SR^Y)_2$, $-P(=S)(SR^Y)_2$, or a hydroxy protecting group;

each R^Y independently is H or C_1-C_6 alkyl optionally substituted with one or more halogen or cyano;

Z is H, or C_1-C_6 alkyl optionally substituted with one or more halogen, $-P(R^Z)_2$, $-P(OR^Z)(N(R^Z)_2)$, $-P(=O)(OR^Z)R^Z$, $-P(=S)(OR^Z)R^Z$, $-P(=O)(SR^Z)R^Z$, $-P(=S)(SR^Z)R^Z$, $-P(=O)(OR^Z)_2$, $-P(=S)(OR^Z)_2$, $-P(=O)(SR^Z)_2$, $-P(=S)(SR^Z)_2$, or a hydroxy protecting group;

each R^Z independently is H or C_1-C_6 alkyl optionally substituted with one or more halogen or cyano;

or Y and Z in Formula (I) together form $-Si(R^L)_2$-O-$Si(R^L)_2$-, wherein each R^L independently is H or C_1-C_6 alkyl;

each R^a independently is H, halogen, or C_1-C_6 alkyl optionally substituted with one or more halogen; or two R^a on two adjacent carbon atoms, together with the two adjacent carbon atoms, form a double bond;

each R^b independently is H, halogen, or C_1-C_6 alkyl optionally substituted with one or more halogen;

R^1 is H, halogen, or C_1-C_6 alkyl optionally substituted with one or more halogen;

R^2 is H, halogen, or C_1-C_6 alkyl optionally substituted with one or more halogen;

R^3 is H, halogen, or C_1-C_6 alkyl optionally substituted with one or more halogen;

R^4 is H, halogen, or C_1-C_6 alkyl optionally substituted with one or more halogen;


each R^5 independently is H, halogen, or C_1-C_6 alkyl optionally substituted with one or more halogen; and


n is an integer ranging from about 0 to about 10.

2. A scaffold or a pharmaceutically acceptable salt thereof, wherein the scaffold comprises:

(i) a Ligand; and

(ii) a Linker Unit, wherein the Linker Unit is:



or








,

wherein variables B, R^1, R^2, R^3, R^4, R^5, Y, Z, R^a, R^b, and n are described herein, and # indicate an attachment to the Ligand.

3. A scaffold or a pharmaceutically acceptable salt thereof, wherein the scaffold comprises:

(i) one or more Nucleic Acid Agent; and

(ii) one or more Linker Unit, wherein each Linker Unit independently is:


wherein variables B, R^1, R^2, R^3, R^4, R^5, W, Y, Z, R^a, R^b, and n are described herein, and ## indicates an attachment to the Nucleic Acid Agent.


4. A conjugate or a pharmaceutically acceptable salt thereof, wherein the scaffold comprises:


(i) one or more Nucleic Acid Agent;


(ii) one or more Ligand; and


(iii) one or more Linker Unit, wherein each Linker Unit independently is:



,


,


,


,


, or


,

wherein variables B, R^1, R^2, R^3, R^4, R^5, Y, Z, R^a, R^b, and n are described herein, # indicate an attachment to the Ligand, and ## indicates an attachment to the Nucleic Acid Agent.

5. The compound, scaffold, or conjugate of any one of the preceding claims, wherein B is H.

6. The compound, scaffold, or conjugate of any one of the preceding claims, wherein B is a nucleobase moiety.

7. The compound, scaffold, or conjugate of any one of the preceding claims, wherein the nucleobase moiety is adenine (A), cytosine (C), guanine (G), thymine (T), or uracil (U).

8. The compound, scaffold, or conjugate of any one of the preceding claims, wherein W is H.

9. The compound, scaffold, or conjugate of any one of the preceding claims, wherein W is C_1-C_6 alkyl.

10. The compound, scaffold, or conjugate of any one of the preceding claims, wherein W is an amino substitution group.

11. The compound, scaffold, or conjugate of any one of the preceding claims, wherein W is fluorenylmethyloxycarbonyl (Fmoc), tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Cbz), optionally substituted acyl, trifluoroacetyl (TFA), benzyl, triphenylmethyl (Tr), 4,4′-dimethoxytrityl (DMTr), or toluenesulfonyl (Ts).

12. The compound, scaffold, or conjugate of any one of the preceding claims, wherein Y is C_1-C_6 alkyl optionally substituted with one or more halogen.

13. The compound, scaffold, or conjugate of any one of the preceding claims, wherein Y is $-P(R^Y)_2$, $-P(OR^Y)(N(R^Y)_2)$, $-P(=O)(OR^Y)R^Y$, $-P(=S)(OR^Y)R^Y$, $-P(=O)(SR^Y)R^Y$, $-P(=S)(SR^Y)R^Y$, $-P(=O)(OR^Y)_2$, $-P(=S)(OR^Y)_2$, $-P(=O)(SR^Y)_2$, $-P(=S)(SR^Y)_2$.

14. The compound, scaffold, or conjugate of any one of the preceding claims, wherein Y is a hydroxy protecting group.

15. The compound, scaffold, or conjugate of any one of the preceding claims, wherein Z is H.


16. The compound, scaffold, or conjugate of any one of the preceding claims, wherein Z is C_1-C_6 alkyl optionally substituted with one or more halogen.


17. The compound, scaffold, or conjugate of any one of the preceding claims, wherein Z is $-P(R^Z)_2$, $-P(OR^Z)(N(R^Z)_2)$, $-P(=O)(OR^Z)R^Z$, $-P(=S)(OR^Z)R^Z$, $-P(=O)(SR^Z)R^Z$, $-P(=S)(SR^Z)R^Z$, $-P(=O)(OR^Z)_2$, $-P(=S)(OR^Z)_2$, $-P(=O)(SR^Z)_2$, $-P(=S)(SR^Z)_2$.

18. The compound, scaffold, or conjugate of any one of the preceding claims, wherein Z is a hydroxy protecting group.

19. The compound, scaffold, or conjugate of any one of the preceding claims, wherein Y and Z in Formula (I) together form $-Si(R^L)_2-O-Si(R^L)_2-$.


20. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or (II'):



(I');


(II');

or a pharmaceutically acceptable salt thereof.


21. The compound of any one of the preceding claims, wherein the compound is of Formula (I-A) or (II-A):



(I-A);


(II-A);

or a pharmaceutically acceptable salt thereof.


22. The compound of any one of the preceding claims, wherein the compound is of Formula (I'-A) or (II'-A):



(I'-A);


(II'-A);

or a pharmaceutically acceptable salt thereof.

23. The compound of any one of the preceding claims, wherein the compound is of Formula (I-B) or (II-B):



(I-B);




(II-B);

or a pharmaceutically acceptable salt thereof.

24. The compound of any one of the preceding claims, wherein the compound is of Formula (I'-B) or (II'-B):





(I'-B);


















(II'-B);










or a pharmaceutically acceptable salt thereof.










25. The compound of any one of the preceding claims, wherein the compound is selected from the group consisting of:









Compound No.	Structure
L-1	
L-2	









L-3	
L-4	
L-5	
L-6	
L-7	
L-8	
L-9	









L-10	 wherein the C_1-C_{30} alkyl is optionally substituted
L-11	 wherein the C_1-C_{30} alkyl is optionally substituted
L-12	 wherein the C_1-C_{30} alkyl is optionally substituted
L-13	
L-14	
L-15	
L-16	
L-17	







L-18	
L-19	
L-20	
L-21	
L-22	
L-23	
L-24	
L-25	 wherein the C_1-C_{30} alkyl is optionally substituted
L-26	







	wherein the C_1-C_{30} alkyl is optionally substituted
L-27	 wherein the C_1-C_{30} alkyl is optionally substituted
L-28	
L-29	
L-30	
L-31	
L-32	
L-33	
L-34	
L-35	







L-36	
L-37	 wherein the C_1-C_{30} alkyl is optionally substituted
L-38	 wherein the C_1-C_{30} alkyl is optionally substituted
L-39	 wherein the C_1-C_{30} alkyl is optionally substituted
L-40	
L-41	
L-42	
L-43	






L-44	
L-45	
L-46	
L-47	
L-48	
L-49	 wherein the C_1-C_{30} alkyl is optionally substituted
L-50	 wherein the C_1-C_{30} alkyl is optionally substituted
L-51	






	wherein the C_1-C_{30} alkyl is optionally substituted
L-52	
L-53	
L-54	
L-55	
L-56	
L-57	
L-58	
L-59	







L-60	
L-61	
L-62	
L-63	
L-64	 wherein the C_1-C_{30} alkyl is optionally substituted
L-65	 wherein the C_1-C_{30} alkyl is optionally substituted







L-66	 wherein the C_1-C_{30} alkyl is optionally substituted
L-67	
L-68	
L-69	
L-70	
L-71	







L-72	
L-73	
L-74	
L-75	
L-76	
L-77	







L-78	
L-79	
L-80	
L-81	
L-82	








L-83	
L-84	
L-85	 wherein the C_1-C_{30} alkyl is optionally substituted
L-86	 wherein the C_1-C_{30} alkyl is optionally substituted
L-87	 wherein the C_1-C_{30} alkyl is optionally substituted



L-88	
L-89	
L-90	
L-91	
L-92	
L-93	

L-94	
L-95	
L-96	
L-97	 wherein the C_1-C_{30} alkyl is optionally substituted
L-98	 wherein the C_1-C_{30} alkyl is optionally substituted
L-99	

	wherein the C_1-C_{30} alkyl is optionally substituted
L-100	
L-101	
L-102	
L-103	
L-104	
L-105	

L-106	
L-107	
L-108	
L-109	 wherein the C_1-C_{30} alkyl is optionally substituted
L-110	 wherein the C_1-C_{30} alkyl is optionally substituted
L-111	 wherein the C_1-C_{30} alkyl is optionally substituted

L-112	
L-113	
L-114	
L-115	
L-116	
L-117	
L-118	

L-119	 and
L-120	

and pharmaceutically acceptable salts thereof.

26. The scaffold of any one of the preceding claims, wherein the scaffold is (Linker Unit)$_p$-((Nucleic Acid Agent)-(Linker Unit)$_s$)$_r$-(Nucleic Acid Agent)$_q$, wherein:

each Linker Unit is independent from another Linker Unit, and each Nucleic Acid Agent is independent from another Nucleic Acid Agent;

each r independently is an integer ranging from 0 to 10;


each s independently is an integer ranging from 0 to 10;

p is an integer ranging from 0 to 10;

q is 0 or 1; and

the scaffold comprises at least one Linker Unit and at least one Nucleic Acid Agent.

27. The scaffold of any one of the preceding claims, wherein the scaffold is



or a pharmaceutically acceptable salt thereof, wherein:

B is a nucleobase moiety;

Y is -P(R^Y)$_2$, -P(OR^Y)($N(R^Y)_2$), -P(=O)(OR^Y)R^Y, -P(=S)(OR^Y)R^Y, -P(=O)(SR^Y)R^Y, -P(=S)(SR^Y)R^Y, -P(=O)(OR^Y)$_2$, -P(=S)(OR^Y)$_2$, -P(=O)(SR^Y)$_2$, -P(=S)(SR^Y)$_2$, or a hydroxy protecting group;






each R^Y independently is H or C_1-C_6 alkyl optionally substituted with one or more halogen or cyano;







Z is $-P(R^Z)_2$, $-P(OR^Z)(N(R^Z)_2)$, $-P(=O)(OR^Z)R^Z$, $-P(=S)(OR^Z)R^Z$, $-P(=O)(SR^Z)R^Z$, $-P(=S)(SR^Z)R^Z$, $-P(=O)(OR^Z)_2$, $-P(=S)(OR^Z)_2$, $-P(=O)(SR^Z)_2$, $-P(=S)(SR^Z)_2$, or a hydroxy protecting group;






each R^Z independently is H or C_1-C_6 alkyl optionally substituted with one or more halogen or cyano; and

n is an integer ranging from about 0 to about 10.



28. The scaffold of any one of the preceding claims, wherein the scaffold is selected from the group consisting of:

Compound No.	Structure
S1-1	
S1-2	
S1-3	
S1-4	
S1-5	

Compound No.	Structure
S1-6	
S1-7	
S1-8	
S1-9	
S1-10	
S1-11	

Compound No.	Structure
S1-12	
S1-13	
S1-14	
S1-15	 and
S1-16	

29. The scaffold of any one of the preceding claims, wherein the scaffold is

or ;





or a pharmaceutically acceptable salt thereof, wherein:







B is a nucleobase moiety;







W is an amino substitution group; and








n is an integer ranging from about 0 to about 10.







30. The scaffold of any one of the preceding claims, wherein the scaffold is selected from the group consisting of:






Compound No.	**Structure**
S2-1	
S2-2	
S2-3	
S2-4	







S2-5	
S2-6	
S2-7	
S2-8	
S2-9	
S2-10	






S2-11	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-12	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-13	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-14	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-15	
S2-16	






S2-17	
S2-18	
S2-19	
S2-20	
S2-21	
S2-22	
S2-23	





S2-24	
S2-25	
S2-26	
S2-27	
S2-28	
S2-29	






S2-30	
S2-31	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-32	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-33	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-34	 wherein the C_1-C_{30} alkyl is optionally substituted






S2-35	
S2-36	
S2-37	
S2-38	
S2-39	
S2-40	






S2-41	
S2-42	
S2-43	
S2-44	
S2-45	





S2-46	
S2-47	
S2-48	
S2-49	
S2-50	





S2-51	
S2-52	
S2-53	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-54	 wherein the C_1-C_{30} alkyl is optionally substituted






S2-55	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-56	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-57	
S2-58	
S2-59	







S2-60	
S2-61	
S2-62	
S2-63	
S2-64	







S2-65	
S2-66	
S2-67	
S2-68	
S2-69	






S2-70	
S2-71	
S2-72	
S2-73	 wherein the C_1-C_{30} alkyl is optionally substituted








S2-74	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-75	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-76	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-77	







S2-78	
S2-79	
S2-80	
S2-81	
S2-82	







S2-83	
S2-84	
S2-85	
S2-86	
S2-87	
S2-88	







S2-89	
S2-90	
S2-91	
S2-92	
S2-93	
S2-94	






S2-95	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-96	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-97	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-98	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-99	





S2-100	
S2-101	
S2-102	
S2-103	
S2-104	
S2-105	
S2-106	





S2-107	
S2-108	
S2-109	
S2-110	
S2-111	
S2-112	





S2-113	
S2-114	
S2-115	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-116	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-117	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-118	






	wherein the C_1-C_{30} alkyl is optionally substituted
S2-119	
S2-120	
S2-121	
S2-122	
S2-123	
S2-124	






S2-125	
S2-126	
S2-127	
S2-128	
S2-129	





S2-130	
S2-131	
S2-132	
S2-133	





S2-134	
S2-135	
S2-136	
S2-137	 wherein the C_1-C_{30} alkyl is optionally substituted





S2-138	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-139	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-140	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-141	






S2-142	
S2-143	
S2-144	
S2-145	
S2-146	







S2-147	
S2-148	
S2-149	
S2-150	
S2-151	








S2-152	
S2-153	
S2-154	
S2-155	








S2-156	
S2-157	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-158	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-159	 wherein the C_1-C_{30} alkyl is optionally substituted






S2-160	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-161	
S2-162	
S2-163	






S2-164	
S2-165	
S2-166	
S2-167	
S2-168	






S2-169	
S2-170	
S2-171	
S2-172	
S2-173	
S2-174	 wherein the C_1-C_{30} alkyl is optionally substituted






S2-175	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-176	
S2-177	
S2-178	
S2-179	
S2-180	
S2-181	



S2-182	
S2-183	
S2-184	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-185	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-186	
S2-187	
S2-188	

S2-189	
S2-190	
S2-191	
S2-192	
S2-193	

S2-194	
S2-195	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-196	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-197	
S2-198	

S2-199	
S2-200	
S2-201	
S2-202	
S2-203	

S2-204	
S2-205	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-206	 wherein the C_1-C_{30} alkyl is optionally substituted
S2-207	
S2-208	

S2-209	 and
S2-210	

31. The conjugate of any one of the preceding claims, wherein the conjugate is (Linker Unit-(Ligand)$_{0\text{-}1}$)$_p$-((Nucleic Acid Agent)-(Linker Unit-(Ligand)$_{0\text{-}1}$)$_s$)$_r$-(Nucleic Acid Agent)$_q$, wherein:

each Linker Unit is independent from another Linker Unit, each Nucleic Acid Agent is independent from another Nucleic Acid Agent, and each Ligand is independent from another Ligand;

each r independently is an integer ranging from 0 to 10;




each s independently is an integer ranging from 0 to 10;








p is an integer ranging from 0 to 10;







q is 0 or 1; and







the conjugate comprises at least one Linker Unit, at least one Nucleic Acid Agent, and at least one Ligand.







32. The conjugate of any one of the preceding claims, wherein the conjugate is selected from the group consisting of:






Compound No.	**Structure**
C-1	
C-2	
C-3	







C-4	
C-5	
C-6	
C-7	
C-8	
C-9	
C-10	






C-11	
C-12	
C-13	
C-14	
C-15	
C-16	






C-17	
C-18	
C-19	
C-20	
C-21	
C-22	





C-23	
C-24	
C-25	
C-26	
C-27	
C-28	






C-29	
C-30	
C-31	
C-32	
C-33	





C-34	
C-35	
C-36	
C-37	
C-38	
C-39	






C-40	
C-41	
C-42	
C-43	
C-44	





C-45	
C-46	
C-47	
C-48	
C-49	





C-50	
C-51	
C-52	
C-53	






C-54	
C-55	
C-56	
C-57	
C-58	







C-59	
C-60	
C-61	
C-62	







C-63	
C-64	
C-65	
C-66	
C-67	






C-68	
C-69	
C-70	
C-71	







C-72	
C-73	
C-74	
C-75	








C-76	
C-77	
C-78	
C-79	
C-80	






C-81	
C-82	
C-83	
C-84	
C-85	
C-86	







C-87	
C-88	
C-89	
C-90	
C-91	
C-92	





C-93	
C-94	
C-95	
C-96	
C-97	






C-98	
C-99	
C-100	
C-101	
C-102	
C-103	





C-104	
C-105	
C-106	
C-107	
C-108	
C-109	
C-110	






C-111	
C-112	
C-113	
C-114	
C-115	





C-116	
C-117	
C-118	
C-119	
C-120	
C-121	






C-122	
C-123	
C-124	
C-125	





C-126	
C-127	
C-128	
C-129	
C-130	





C-131	
C-132	
C-133	
C-134	






C-135	
C-136	
C-137	
C-138	
C-139	







C-140	
C-150	
C-151	
C-152	







C-153	
C-154	
C-155	
C-156	
C-157	







C-158	
C-159	
C-160	
C-161	






C-162	
C-163	
C-164	
C-165	





C-166	
C-167	
C-168	
C-169	
C-170	






C-171	
C-172	
C-173	
C-174	
C-175	
C-176	





C-177	
C-178	
C-179	
C-180	
C-181	
C-182	




C-183	
C-184	
C-185	
C-186	
C-187	
C-188	



C-189	
C-190	
C-191	
C-192	
C-193	



C-194	
C-195	
C-196	
C-197	

C-198	
C-199	
C-200	
C-201	
C-202	

C-203	
C-204	
C-205	
C-206	

C-207	
C-208	 and
C-209	

33. The scaffold or conjugate of any one of the preceding claims, wherein the ligand comprises  or .

34. The scaffold or conjugate of any one of the preceding claims, wherein the ligand comprises  or .

35. The scaffold or conjugate of any one of the preceding claims, wherein the ligand

comprises a lipid, a peptide moiety, or an antibody moiety.

36. The scaffold or conjugate of any one of the preceding claims, wherein the Nucleic Acid Agent comprises an oligonucleotide.

37. A pharmaceutical composition comprising the compound, scaffold, or conjugate of the any one of the preceding claims.

38. The conjugate of any one of the preceding claims for use as a medicament.

39. Use of the conjugate of any one of the preceding claims in the manufacture of a medicament for modulating the expression of a target gene in a subject, delivering a Nucleic Acid Agent to a subject, or treating or preventing a disease in a subject in need thereof.

40. The use of claim 39, wherein the disease is cancer or viral infection.